Biomarker Study for Ichthyosis

Enrolling by invitation at 4 trial locations

Overseen By Amy Paller, MD

Age: < 65

Sex: Any

Trial Phase: Academic

Sponsor: Northwestern University

Must not be taking: Immunosuppressants, Anti-inflammatories

Disqualifiers: Inflammatory disease, Atopy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to better understand ichthyosis, a group of genetic skin disorders that cause dry, thick, scaly skin. Researchers are examining specific signals in the blood and skin to identify patterns that could lead to future treatments through biomarker analysis. The study focuses on differences between Netherton syndrome and lamellar ichthyosis. Individuals with ichthyosis who haven't recently used certain medications might be suitable candidates for this trial. As an unphased study, this trial offers participants the chance to contribute to groundbreaking research that could pave the way for new treatments.

Will I have to stop taking my current medications?

If you are taking systemic or topical immunosuppressants, you will need to stop them at least a month or a week before the study, respectively. You should also avoid applying emollients to the biopsy sites within 12 hours before the biopsy.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to identify skin and blood biomarkers for ichthyosis, which could revolutionize how we understand and treat this condition. Unlike traditional treatments that focus on alleviating symptoms with topical creams or oral retinoids, biomarker analysis seeks to uncover the underlying biological indicators of the disease. This approach could lead to more targeted therapies in the future, offering personalized treatment options and potentially more effective results for individuals with ichthyosis.

Are You a Good Fit for This Trial?

Inclusion Criteria

Control and ichthyosis subjects may be of either sex and must be between 1-60 years of age at the time of enrollment

Ichthyosis subjects include individuals with a diagnosis Netherton syndrome, lamellar ichthyosis, or other ichthyosis subtypes

Ichthyosis subjects should not have administered systemic immunosuppressant therapy in the month before the study

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Biomarker Analysis

Participants' skin and blood samples are collected and analyzed for gene expression and cellular infiltrates

12 months

Follow-up

Participants are monitored for safety and effectiveness after biomarker analysis

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Biomarker Analysis

Who Is Running the Clinical Trial?

Northwestern University

Lead Sponsor

Trials

1,674

Recruited

989,000+

Galderma R&D

Industry Sponsor

Trials

303

Recruited

60,700+

Flemming Ørnskov

Galderma R&D

Chief Executive Officer since 2019

MD, MPH

Baldo Scassellati Sforzolini

Galderma R&D

Chief Medical Officer

MD, PhD

Icahn School of Medicine at Mount Sinai

Collaborator

Trials

933

Recruited

579,000+